Targeted Therapy in Early Stage Non-small Cell Lung Cancer.
Si-Yang LiuSi-Yang Maggie LiuWen-Zhao ZhongYi-Long WuPublished in: Current treatment options in oncology (2022)
Tyrosine kinase inhibitors (TKIs) have dramatically improved tumor response rates and survival benefits in advanced oncogenic non-small-cell lung cancer (NSCLC). Given the impressive success, a renewed interest has been raised in the study of these agents in the perioperative setting. Preliminary data have shown dramatic effectiveness compared to conventional chemotherapy. Given the explicit need to induce durable responses and raise cure rates, we summarize the current progression, identify key challenges, and raise potential opportunities for perioperative targeted therapy that range from precise biomarkers to optimal adjuvant regimens for individual patients. As perioperative treatment indeed provides researchers with a unique platform to address the challenges mentioned above, investigators could obtain a comprehensive analysis of genomic profiling and trace resistance mechanisms. Multidisciplinary collaboration and adaptive clinical trial designs are warranted to integrate translational research into personalized perioperative TKI treatment paradigms.
Keyphrases
- early stage
- cardiac surgery
- patients undergoing
- clinical trial
- small cell lung cancer
- randomized controlled trial
- end stage renal disease
- ejection fraction
- systematic review
- prognostic factors
- advanced non small cell lung cancer
- gene expression
- transcription factor
- risk assessment
- combination therapy
- acute kidney injury
- machine learning
- replacement therapy
- tyrosine kinase
- study protocol
- locally advanced
- single cell
- heavy metals
- deep learning
- sentinel lymph node
- big data
- quality improvement
- rectal cancer
- data analysis